8 digital health and life sciences executives share their hot takes and insights from the recent annual JPM Healthcare Conference 2024
Virgil Bretz, co-founder and CEO of MacroHealth
“The annual JP Morgan Healthcare Conference is still…
Continue Reading
I travel to a lot of the major conferences in the healthcare world, but I didn’t make it to this year’s J.P. Morgan Healthcare Conference in San Francisco. Because we all have FOMO from…
Continue Reading
Are you a healthcare startup in health tech, diagnostics, medtech, or biotech? If so, you should consider applying to the MedCity News startup pitch contest at the INVEST conference at the Ritz Carlton in…
Continue Reading
What You Should Know:
– Unnatural Products, Inc. (UNP), a biotech company harnessing the power of AI and chemistry to design the next generation of targeted therapeutics, has secured $32M in Series A funding.
– Led…
Continue Reading
Collaborating for biologic breakthroughs, IBM and Boehringer Ingelheim merge genAI with foundation models. IBM’s cutting-edge AI expedites antibody discovery, targeting diseases like cancer, autoimmune disorders, and infections. Boehringer’s validation of refined antibodies affirms in-silico…
Continue Reading
Vivodyne started as an idea between Co-Founders Andrei Georgescu (left), now Vivodyne’s CEO, and UPenn Professor Dan Huh (right), now Vivodyne’s CSO, while Andrei performed his Ph.D. graduate studies in Huh’s bioengineering research lab….
Continue Reading
Philadelphia-based AI-enabled biotech company Vivodyne announced it closed a $38 million seed funding round led by Khosla Ventures.CS Ventures, Kairos Ventures, Bison Ventures and MBX Capital also participated in the round.
WHAT THEY DO
Vivodyne is…
From left: Hubert Zajicek, Health Wildcatters CEO and co-founder; Somer Baburek, Hera Biotech CEO; and Katie Adams, MedCity News Senior Reporter.
At the MedCity INVEST Digital Health conference in Dallas, held in collaboration with Health Wildcatters,…
What You Should Know:
Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round.This funding round positions Gero to continue internal drug development programs, grow its…
Continue Reading
In the relentless global battle against cancer, generative artificial intelligence (Gen AI) has emerged as a powerful tool in oncology’s arsenal. With the capacity to analyse vast datasets, simulate complex molecular interactions, and tailor…
Continue Reading
